CLINICAL_TRIALS
trial_result
· 2010-01-11
Clinical Trial Update: A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069) [Phase 3]
Summary
Phase 3 trial evaluating two doses of VAQTA in healthy children aged 12 to 23 months. Results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis A Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2010-01-11